Based on the Gland Pharma Limited stock forecast from 2 analysts, the average analyst target price for Gland Pharma Limited is INR 1,810.00 over the next 12 months. Gland Pharma Limited’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Gland Pharma Limited is Slightly Bearish, which is based on 5 positive signals and 9 negative signals. At the last closing, Gland Pharma Limited’s stock price was INR 1,776.90. Gland Pharma Limited’s stock price has changed by +1.40% over the past week, -0.97% over the past month and +35.52% over the last year.
No recent analyst target price found for Gland Pharma Limited
No recent average analyst rating found for Gland Pharma Limited
Company Overview Gland Pharma Limited
Gland Pharma Limited engages in manufacturing and sale of injectable formulation in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. The company engages in research and development of pharmaceutical API products including synthesis of complex drug molecules, such as LMWH, corticosteroids, peptides, and cytotoxic molecules. The company offers its products for various therapeutic categories, such as anti-malarial, anti-infectives, anti-neoplastic, blood related, cardiac, gastro intestinal, gynecological, hormones, neuro/Cns, ophthal/ontological, and other areas, as well as pain and analgesics, respirator, and vitamins, minerals and nutrients; and offers contract development services. The company was incorporated in 1978 and is headquartered in Hyderabad, India. Gland Pharma Limited operates as a subsidiary of Fosun Pharma Industrial Pte. Ltd. Read Less
Gland Pharma Limited engages in manufacturing and sale of injectable formulation in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. The company engages in research and development of pharmaceutical API products including synthesis of complex...Read More
Frequently Asked Questions About Gland Pharma Limited (GLAND:NSE) Stock
Based on ratings from 2 analysts Gland Pharma Limited's stock is Buy . Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 1 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on GLAND:NSE's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for GLAND:NSE is INR 1,810.00 over the next 12 months. The maximum analyst target price is INR 1920 while the minimum anlayst target price is INR 1700.
GLAND:NSE stock's Price/Earning ratio is 43.66.
Our analysis grades GLAND:NSE stock's Price / Earning ratio at F. This means that GLAND:NSE stock's Price/Earning ratio is above 73% of the stocks in the Drug Manufacturers - General sector in the NSE exchange.
Based on this GLAND:NSE may be a overvalued for its sector.
The last closing price of GLAND:NSE's stock was INR 1,776.90.
The most recent market capitalization for GLAND:NSE is INR 288.19B.
Based on targets from 2 analysts, the average taret price for GLAND:NSE is projected at INR 1,810.00 over the next 12 months.
This means that GLAND:NSE's stock price may go up by +1.86% over the next 12 months.
We can't find any ETFs which contains Gland Pharma Limited's stock.
As per our most recent records Gland Pharma Limited has 4,585 Employees.
Gland Pharma Limited's registered address is Plot No. 11 & 84, TSIIC Phase: IV, Hyderabad, India, 502307.
You can get more information about it from Gland Pharma Limited's website at https://www.glandpharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low debt
The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
What not to like
Poor capital utilization
The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.
Poor return on assets
The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Poor return on equity
The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for GLAND:NSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
